The Number One Question For Valeant: What Next?
This article was originally published in The Pink Sheet Daily
Executive Summary
Now that the hostile bid for Cephalon has fallen through, Valeant's CEO sees "no shortage of exciting opportunities" but says there's no hurry.
You may also be interested in...
Valeant’s Latest M&A Gambit Hits Snag With Ista’s Rejection Of $314 Million Buyout Offer
The industry’s third largest ophthalmology company turns down a $6.50-per-share offer, saying the bid grossly undervalues the potential of its pipeline.
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.
Valeant Adds To Dermatology Business By Acquiring Sanofi's Dermik For $425 Million
Sanofi divests its U.S and Canadian dermatology business to focus on core areas; Valeant beefs up skin care franchise and adds manufacturing capacity.